Long Covid Newsletter
Issue #22February 2, 20267 studies

Long COVID hits women harder with more symptoms, while early treatments show promise

New research is painting a clearer picture of who gets hit hardest by long COVID—and what might actually help. From sex differences in immune responses to promising drug treatments, here's what scientists learned this week.

🧬 Women Face Double Burden: More Long COVID Symptoms Plus Weaker Immune Response

  • 34 people with long COVID (lasting 9 months to 5 years) were compared to 26 recovered controls, revealing stark sex differences in both symptoms and immune function

  • Women reported higher symptom burdens, especially persistent fatigue and brain fog that worsened with age and disease duration, while men showed no clear age-related patterns

  • Female patients had reduced CD8+ T cell activity (the cells that kill infected cells) and lower levels of key immune proteins like granzyme K and perforin, suggesting their bodies struggle more to clear viral remnants

Why it matters: The weaker cytotoxic response in women may explain why they experience more neurological symptoms and longer recovery times, pointing to the need for sex-specific treatments.

🎖️ Top 10% journal 🔗 Biology of sex differences Journal Article 🗓️ Jan 28

Key Findings

🎯 AI Predicts Which Patients Will Respond to Steroid Treatment

  • Machine learning analysis of 330 long COVID patients across three hospitals identified who benefits most from low-dose methylprednisolone treatment

  • The AI model achieved strong predictive accuracy (AUCs ranging from 0.72 to 0.87) and pinpointed 7 key variables that determine treatment success

  • Researchers created a user-friendly nomogram that doctors can use to predict individual patient responses before starting treatment

💡 Personalized medicine for long COVID may soon move from guesswork to data-driven predictions.
🎖️ Top 10% journal 🔗 iScience Journal Article 🗓️ Jan 26

⚠️ Early Antibody Treatment Linked to Unexpected Autoimmune Risk

  • Analysis of 19,689 hospitalized COVID patients in Singapore found that early monoclonal antibody treatment didn't reduce overall long COVID risk

  • Patients who received early antibodies had 2.2 times higher risk of developing autoimmune diseases, particularly lupus and rheumatoid arthritis

  • The treatment was also associated with 1.8 times higher risk of blood clots, though this became less significant after accounting for healthcare usage patterns

💡 Early COVID treatments may carry hidden long-term immune consequences that warrant closer monitoring.
🎖️ Top 10% journal 🔗 Int J Infect Dis Journal Article 🗓️ Jan 27

🫁 Hidden Lung Damage Revealed Despite Normal Breathing Tests

  • 60 long COVID patients (average age 60, 57% female) underwent comprehensive lung testing including CT scans and specialized function tests

  • While 88% had normal spirometry results, 75% showed impaired gas exchange (DLCO) and 35% had reduced total lung capacity

  • CT scans revealed ground-glass opacities in 65% and fibrotic changes in 55%, despite normal chest X-rays in 58% of cases

💡 Standard breathing tests miss significant lung damage in long COVID patients, requiring more comprehensive evaluation.
Top 20% journal 🔗 Biomedicines Journal Article 🗓️ Jan 28

🧠 Brain Changes Mirror Alzheimer's Risk in Long COVID Patients

  • Brain scans of 86 long COVID patients showed enlarged choroid plexus (brain fluid-producing structures) and reduced blood flow compared to 67 recovered patients and 26 healthy controls

  • Choroid plexus volume correlated positively with Alzheimer's biomarkers including phosphorylated tau217 (r = 0.54) and glial protein GFAP (r = 0.35)

  • Both brain changes were associated with cognitive decline measured by standard dementia screening tools

💡 Long COVID brain changes may serve as early warning signs for Alzheimer's-related cognitive decline.
🥈 Top 2% journal 🔗 Alzheimers Dement Journal Article 🗓️ Jan 30

🏃‍♀️ Exercise Training Rewires Immune Messaging in Recovery

  • 14 adults with long COVID completed 10 weeks of aerobic training while researchers analyzed circulating RNA messages in blood vesicles

  • After training, 53 genes changed their expression during peak exercise (3 increased, 50 decreased), primarily involving inflammation and metabolism pathways

  • No viral RNA was detected in blood samples, but exercise enhanced the body's ability to mount dynamic molecular responses during exertion

💡 Exercise may help long COVID patients by improving their body's ability to adapt molecularly to physical stress.
Top 20% journal 🔗 Scientific reports Clinical Trial 🗓️ Jan 26

💊 Antiviral Drug Cuts Long COVID Risk in Immunocompromised Patients

  • Retrospective study found that nirmatrelvir/ritonavir (Paxlovid) treatment during acute COVID significantly reduced long COVID risk in immunodeficient patients

  • The analysis specifically focused on high-risk populations who are often excluded from clinical trials but may benefit most from early intervention

  • Results emphasize the need for clinical trials that include immunocompromised patients rather than excluding them

💡 Early antiviral treatment may be especially important for protecting immunocompromised patients from long-term complications.
🔗 Journal of human immunity Journal Article 🗓️ Jan 29

Implications

This week's research reveals long COVID as a complex condition requiring personalized approaches—from AI-guided steroid treatments to sex-specific therapies addressing women's heightened immune dysfunction. While some early treatments show promise for high-risk groups, others carry unexpected autoimmune risks, highlighting the need for careful long-term monitoring as we develop more targeted interventions.

Studies in this issue

Primary sources used for this newsletter.

  1. Long-term differences between men and women in symptoms and immune response after long COVID
    main storyBiology of sex differences2026-01-28PMID 41593681
  2. Changes in blood particle RNA linked to long COVID and exercise-related gene activity
    key findingScientific reports2026-01-26PMID 41588020
  3. Changes in the brain’s fluid-producing tissue after long COVID and their links to Alzheimer's disease risk
    key findingAlzheimer's & dementia : the journal of the Alzheimer's Association2026-01-30PMID 41612939
  4. Using understandable machine learning to predict how well low-dose methylprednisolone works in long COVID
    key findingiScience2026-01-26PMID 41585473
  5. Lung Problems in Long COVID Patients: A Look Back Study
    key findingBiomedicines2026-01-28PMID 41595678
  6. Nirmatrelvir/ritonavir may lower long COVID risk in people with weak immune systems
    key findingJournal of human immunity2026-01-29PMID 41608121
  7. Early use of neutralizing antibodies and long-term COVID-19 symptoms
    key findingInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026-01-27PMID 41592666

Continue reading

All Long Covid issues